01167 JACOBIO-B
- 1.730
- +0.040+2.37%
JACOBIO-B News
Jacobio Pharmaceuticals Plans Auditor Change
Jacobio Pharmaceuticals Group Co (HKG:1167) has suggested that Deloitte Touche Tohmatsu be appointed as the company's new auditor during the next annual general meeting, according to a Wednesday filin
Gacos-B proposes to appoint Deloitte as independent auditor
Gacos-B (01167) announced that PricewaterhouseCoopers will expire and retire as the company's auditor at the end of the company's annual general meeting of shareholders expected to be held on June 7, 2024. The board of directors has decided not to renew PricewaterhouseCoopers as the company's auditor based on the recommendations of the company's audit committee. According to the company's articles of association and as recommended by the Company Audit Committee, the board of directors has decided to recommend the appointment of Deloitte Guan Huang Chen Fang as the company's independent auditor. It will take effect from the end of the annual general meeting of shareholders until after the end of the company's next annual general meeting of shareholders, but only after the end of the company's next annual general meeting of shareholders
Gacos-B (01167.HK) intends to appoint Deloitte as independent auditor
On April 24, Gelonghui announced Gacos-B (01167.HK), the board of directors announced that PricewaterhouseCoopers will retire as the company's auditor. The Board of Directors has resolved to recommend the appointment of Deloitte Guan Huang Chen Fang Certified Public Accountants (“Deloitte”) as the Company's independent auditor, effective from the end of the Annual General Meeting of Shareholders.
加科思-B：2023年度報告
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention
Jacobio Pharmaceuticals Group Co (HKG:1167) presented the results of two preclinical evaluations of its PARP7 inhibitor JAB-26766, and its p53 Y220C reactivator JAB-30355, at the ongoing American Asso
Gacos-B (01167.HK) Presents Preclinical Data for PARP7 Inhibitor JAB-26766 and P53 Activator JAB-30355 at 2024 AACR Conference
Gelonghui, April 9 | Gacos-B (01167.HK) announced that the company announced the pre-clinical evaluation results of the PARP7 inhibitor JAB-26766 and the p53 Y220C activator JAB-30355 in summary form at the 2024 American Association for Cancer Research (AACR) annual meeting to be held from April 5 to April 10, 2024. JAB-26766 is an effective orally bioavailable PARP7 inhibitor. It is more than 1800 times more selective for PARP7 than PARP2. JAB-26766 as a single drug
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses
Jacobio Pharmaceuticals (HKG:1167) narrowed its loss attributable to owners in 2023 to 359.1 million yuan, or 0.46 yuan per share, from an attributable loss of 371.9 million yuan, or 0.49 yuan per yea
Gacos releases 2023 annual results report, core projects are about to submit new drug marketing applications
BEIJING, SHANGHAI, AND BOSTON, March 29, 2024/PRNewswire/ -- Gacos Pharmaceuticals (1167.HK) released its 2023 annual results report. During the performance period, revenue was 63.5 million yuan, R&D investment was 372 million yuan, and a capital balance of 1.2 billion yuan at the end of 2023. Gacos also announced recent business developments and expected milestones. Dr. Wang Yinxiang, Chairman and CEO of Gacos Pharmaceuticals, said, “In the past year, several Gacos projects have progressed, and the SHP2 inhibitor JAB-3312 combined with Golerese has been approved to conduct phase III registered clinical trials in China.
Gacos-B (01167) achieved revenue of 63.52 million yuan in 2023
Gacos-B (01167) announced results for the year ended December 31, 2023. The group recorded revenue of 6...
加科思-B：截至2023年12月31日止年度的年度業績公告
Gacos-B (01167.HK) will hold a board meeting on March 28 to approve the full year results
Gelonghui, March 18 | Gacos-B (01167.HK) announced that the company will hold a board meeting on March 28, 2024 to approve the annual results of the company and its subsidiaries for the year ended December 31, 2023.
JACOBIO-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Gacos-B (01167) rose more than 23% in the afternoon. Clinical trial application for a new drug to treat solid tumors was recently approved in the US
The Zhitong Finance App learned that Gacos-B (01167) rose more than 23% in the afternoon. As of press release, it rose 19.51% to HK$1.96, with a turnover of HK$11.3326 million. According to the news, Gacos previously announced that the new drug clinical trial application (IND) for its self-developed P53 Y220C activator JAB-30300 has been approved by the US Food and Drug Administration (FDA). According to reports, currently only one similar project for the P53 Y220C activator in the world is in the first clinical phase. The JAB-30300 is expected to be one of the first products to be launched. Additionally, add
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16%
The US Food and Drug Administration granted Jacobio Pharmaceuticals Group (HKG:1167) clearance for phase 1/2a clinical trials of its JAB-30300 drug, a Friday filing said. The trial will assess the saf
Changes in Hong Kong stocks | Gacos-B (01167) is now up more than 12%, and clinical trial applications for new drugs to treat solid tumors have been approved in the US
Gacos-B (01167) rose more than 18% during the intraday period. As of press release, it was up 12.29% to HK$2.65, with a turnover of HK$21.261,600.
Gacos-B (01167.HK): P53 Y220C activator JAB-30300 new drug clinical trial application (IND) approved in the US
Gelonghui March 1 | Gacos-B (01167.HK) announced that the new drug clinical trial application (“IND”) for the P53 Y220C activator JAB-30300 developed independently by the company has been approved by the US Food and Drug Administration (“FDA”). Gacos will conduct phase i/IIa clinical trials for advanced solid tumors in the US to evaluate the safety and efficacy of JAB30300. At the same time, Gacos plans to submit clinical applications for new drugs to the Drug Evaluation Center of the State Drug Administration in China. After approval, clinical trials will be carried out simultaneously in China and the US. P53 is a human cancer
Pharmaceutical stocks generally rose, Genting Xinyao (01952) rose 7.37%. Institutions say that the short-term overfall in the pharmaceutical industry is expected to usher in a phased rebound
Jinwu Financial News | Pharmaceutical stocks generally rose, Genting Xinyao (01952) rose 7.37%, Pharmaceutical (02269) rose 5.46%, Pharmaceutical Kangde (02359) rose 5.3%, Kingsley Biotech (01548) rose 4.46%, Gacos (01167) rose 4.04%, and Tiger Pharmaceuticals (03347) rose 3.85%. According to the Huajin Securities Research Report, 1) Short-term: The pharmaceutical industry has fallen sharply in the short term and is expected to usher in a phased rebound. From a rebound perspective, it is recommended to allocate individual stocks in sectors with large losses in the previous period. The disclosure of the 2023 annual report performance forecast has been completed. Traditional Chinese medicine blood products and other sectors
Gacos (01167) was approved for the third phase of the joint trial of the two core projects and received consecutive brokerage buying ratings
Gacos Pharmaceuticals (01167) recently announced that its self-developed SHP2 inhibitor JAB-3312 in combination with the KRAS G12C golerese inhibitor has been approved for phase III clinical trials in China. This incident marks that SHP2, a target that has not yet been developed, has officially entered phase III clinical trials, a critical step until it is approved for marketing. The clinical trial approved this time was a randomized control. The experimental group was a combination of SHP2 and KRAS G12C, while the control group was the current “gold standard” for first-line non-small cell lung cancer - PD-1 in combination with chemotherapy. This means that the two oral medications are
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13%
China's National Medical Products Administration approved Jacobio Pharmaceuticals Group's (HKG:1167) phase 3 trial for the combination of Glecirasib and JAB-3312 as a treatment for non-small cell lung
Changes in Hong Kong stocks | Gacos-B (01167) fell more than 7% and was excluded. The loss of the Hong Kong Stock Connect Index increased 30% year-on-year in the first half of last year
Gacos-B (01167) fell by more than 7%. As of press release, it was down 7.14% to HK$2.6 million, with a turnover of HK$4.950,800.
Analysis
Price Target
No Data
